News
Learning about nutrition can empower patients with chronic diseases, according to Melanie Betz, MS, RD, CSR, FNKF, FAND, a ...
Adults with a mental illness experienced weight loss and glycemic benefits with use of a GLP-1 without worsening of mental ...
Dermatology patients living in the most disadvantaged neighborhoods were three times more likely to receive a diagnosis of ...
In this Healio Video Perspective from the ASCRS meeting, Brandon D. Ayres, MD, discusses the effectiveness and safety of a 27 ...
Nutrition is critical for combating chronic diseases in the United States, but research on optimal diets is inconsistent, ...
Deaths attributed to both acute heart attack and obesity rose between 2007 and 2019, according to findings from the CDC ...
Researchers projected CT use in 2023 would lead to more than 100,000 future cancer diagnoses, and if trends continued, may ...
Heightened exposure levels to particulate matter before COVID-19 hospitalization raised the odds for poor outcomes in ...
Careful examination of clinical trial data and a better understanding of risk factors can help rheumatologists determine if a ...
Results presented here showed medial patellofemoral ligament reconstruction with or without tibial tubercle osteotomy yielded high return-to-sports rates. However, patients were able to return to ...
As recently as March, the FDA approved the IL-23 inhibitor guselkumab (Tremfya, Johnson & Johnson/Janssen) for patients with Crohn’s disease, offering both IV and subcutaneous induction options.
In this video, Ursula A. Matulonis, MD, shares that although data from the REFRaME-O1 trial of luveltamab tazevibulin were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results